Annexon, Inc. (ANNX)
- Previous Close
4.8300 - Open
4.8800 - Bid 4.8900 x 800
- Ask 4.9900 x 400
- Day's Range
4.8300 - 5.0300 - 52 Week Range
1.5700 - 8.4000 - Volume
98,547 - Avg. Volume
1,888,714 - Market Cap (intraday)
456.52M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4600 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.20
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
www.annexonbio.comRecent News: ANNX
Performance Overview: ANNX
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANNX
Valuation Measures
Market Cap
446.35M
Enterprise Value
212.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.60%
Return on Equity (ttm)
-50.60%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-120.74M
Diluted EPS (ttm)
-1.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
264.95M
Total Debt/Equity (mrq)
11.73%
Levered Free Cash Flow (ttm)
-73.53M